GlassScriptPhysician profile
Cole Hembre
NPI 1023423944
$9,782.90
in general payments reported to CMS, 2019-2025
11 companies · $4,860 in 2025
The $4,860 reported for 2025 was more than what 96% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.26 · 2021: $2,440 · 2022: $1,885 · 2023: $206 · 2024: $305 · 2025: $4,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,200 · Travel and Lodging: $1,237 · Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,200.00 |
| Travel and Lodging | $1,236.93 |
| Food and Beverage | $934.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Maxx Health INC | $3,885.97 | 2025 | Summa Ortho Optossol Compression Device, Summa Ortho Optossol Compression Device |
| Paragon 28, INC. | $2,739.31 | 2022-2025 | Portfolio, Ttc Nail, Trauma |
| Arthrex, INC. | $1,240.00 | 2021 | |
| Southern Edge Orthopaedics, INC. | $1,200.00 | 2021 | |
| Organogenesis INC. | $264.82 | 2023-2024 | Puraply, Novachor, Apligraf |
| Mimedx Group, INC. | $115.16 | 2024 | |
| Curonix LLC | $87.27 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Depuy Synthes Sales INC. | $86.26 | 2019 | |
| Anika Therapeutics, INC. | $66.37 | 2023 | Tactoset |
| Alafair Biosciences, INC. | $65.00 | 2024 | Versawrap |
| Stryker Corporation | $32.74 | 2025 | Valor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cole Hembre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.